Prevention of allergy in children

Abstract

The present invention relates to a use of bacterial superantigens in the manufacture of a pharmaceutical composition for mucous membrane administration for the prevention of inflammatory disorders in newborn infants, such pharmaceutical compositions, as well as method for prevention of inflammatory disorders.

1 . A use of bacterial superantigens in the manufacture of a pharmaceutical composition for mucous membrane administration in newborn infants for the prevention of inflammatory disorders.  
   
   
       2 . A use according to  claim 1  wherein the pharmaceutical composition is comprised of at least one of the  Staphylococcus aureus  enterotoxin producing strains.  
   
   
       3 . A use according to  claim 1  wherein the pharmaceutical composition is comprised of at least one of the  Staphylococcus aureus  enterotoxins A, B, C, D, E, or TSST-1.  
   
   
       4 . A use according to  claim 1  wherein the superantigen in the pharmaceutical composition is  Staphylococcus aureus  enterotoxin A.  
   
   
       5 . A use according to  claim 1  wherein the superantigen in the pharmaceutical composition is  Staphylococcus aureus  enterotoxin B.  
   
   
       6 . A use according to  claim 1  wherein the superantigen in the pharmaceutical composition is  Staphylococcus aureus  enterotoxin C.  
   
   
       7 . A use according to  claim 1  wherein the superantigen in the pharmaceutical composition is  Staphylococcus aureus  enterotoxin D.  
   
   
       8 . A use according to  claim 1  wherein the superantigen in the pharmaceutical composition is  Staphylococcus aureus  enterotoxin E.  
   
   
       9 . A use according to  claim 1  wherein the superantigen in the pharmaceutical composition is  Staphylococcus aureus  enterotoxin TSST-1.  
   
   
       10 . A use according to  claim 1  wherein the pharmaceutical composition is comprised of at least one of the  Staphylococcus aureus  enterotoxins A, B, C, D, E, or TSST-1 or a derivative thereof.  
   
   
       11 . A use according to  claim 1 , wherein the pharmaceutical composition is to be administered onto the intestinal mucous membrane.  
   
   
       12 . A use according to  claim 1 , wherein the pharmaceutical composition is to be administered onto the nasal mucous membrane.  
   
   
       13 . A use according to  claim 11  wherein the pharmaceutical composition according to  claim 3  is to be administered to newborn infants within 3 months after birth.  
   
   
       14 . A use according to  claim 11  wherein the pharmaceutical composition is to be administered to newborn infants within one week after birth.  
   
   
       15 . A use according to  claim 11  wherein the pharmaceutical composition is to be administered to newborn infants within 6 days after birth.  
   
   
       16 . A use according to  claim 11  wherein the pharmaceutical composition is to be administered to newborn infants within 5 days after birth.  
   
   
       17 . A use according to  claim 11  wherein the pharmaceutical composition is to be administered to newborn infants within 4 days after birth.  
   
   
       18 . A use according to  claim 11  wherein the pharmaceutical composition is to be administered to newborn infants within 3 days after birth.  
   
   
       19 . A use according to  claim 1  wherein the pharmaceutical composition is generating regulatory T-cells in vivo.  
   
   
       20 . A use according to  claim 1  wherein the pharmaceutical composition is generating CD25 +  regulatory T-cells in vivo.  
   
   
       21 . A use of the pharmaceutical composition according to  claim 1  wherein the inflammatory disorder is an allergy.  
   
   
       22 . A use of the pharmaceutical composition according to  claim 1  wherein the inflammatory disorder is an inflammatory disease.  
   
   
       23 . A use of the pharmaceutical composition according to  claim 1  wherein the inflammatory disorder is an autoimmune disease.  
   
   
       24 - 26 . (canceled)  
   
   
       27 . Method for inflammatory disorders in humans, by administering a therapeutic effective amount of a superantigen to mucous membranes of newborn infants no later than 7 days after birth suppressing immune responses to antigens other than the superantigen itself.